Description:

This initiative encompasses two different migraine studies focused on the pediatric target population. This study will evaluate the effectiveness of a medication already approved for treating adult migraine attacks. For this study, we will enroll adolescents that are experiencing 1-8 migraine attacks in a one-month period. One study is shorter with a 19-week timespan with 4 study appointments, while the second study will last 58 weeks with 13 office visits.  

Qualified Participants are: 

• Between 12-17 years of age 

• Must have 1-8 migraines per month on average. 

Location:

6210 Brandt Pike, Suite 102

Dayton, Ohio 45424

(937) 912-4369